Cassava Sciences Inc (SAVA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.72 (+5.23%), Market cap $0.11B, 52-week low–high $1.21 ~ $4.64.
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.
Financial statements, price targets, institutional (13F) holdings and related news for Cassava Sciences Inc are updated in real time on BlackAll Trade.
Cassava Sciences Inc trades at $0.72 (+5.23%). Real-time quotes and charts are available on BlackAll Trade.
Cassava Sciences Inc has a market cap of about $0.11B.
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is c